These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Albumin-Bilirubin Score Predicts Short-Term Mortality in Patients with Hepatitis B Virus-Related Decompensated Cirrhosis.
    Author: Qi XT.
    Journal: Clin Lab; 2018 May 01; 64(5):777-783. PubMed ID: 29739046.
    Abstract:
    BACKGROUND: The albumin-bilirubin (ALBI) score is a new index for assessing the severity of liver dysfunction. Hepatitis B virus (HBV) related decompensated cirrhosis (HBV-DeCi) has a high short-term mortality rate. The purpose of this study was to elucidate the prognostic role of the ALBI score in patients with HBV-DeCi. METHODS: This retrospective study included 81 patients who had been diagnosed with HBV-DeCi. All patients were followed up with for at least 2 months, and the relationships between prognosis and ALBI score were analysed. RESULTS: The ALBI score was positively correlated with the model for end-stage liver disease (MELD) score and Child-Turcotte-Pugh score. Moreover, non-surviving patients had a significantly higher ALBI score than surviving patients (-0.79 vs. -1.16, respectively; p = 0.001). Multivariate analysis suggested that the ALBI and MELD scores were independent predictors of 1-month mortality in HBV-DeCi patients (p < 0.05). CONCLUSIONS: The ALBI score is a simple biomarker to predict 1-month mortality in patients with HBV-DeCi and may assist physicians in determining treatment options.
    [Abstract] [Full Text] [Related] [New Search]